RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its 2007
financial results. For the twelve months ending December 31, 2007, sales
decreased from $1,514,491 in 2006 to $1,104,325 in 2007. In 2006 total sales
registered a high due to the confluence of favourable climatic and market
conditions. 2007 sales reflect a higher plateau as compared to years prior to
2006. Sales for FeraMAX(TM) were modest in 2007 as it was not yet listed on
various formularies, restricting its reimbursement.


Gross Margins increased to 69.0% in 2007, from 67.8% in the year ago period
primarily because of margin improvement efforts and the lower cost of USD input
costs.


The company incurred a loss of ($125,991) in 2007 compared to a profit of
$383,145 in 2006. This loss is predominantly due to selling and marketing
expenses to promote FeraMAX(TM) which was first shipped in April 2007 and lower
sales of Protect-It(R) in 2007 as compared to 2006.


Total positive cash flow for 2007 was $27,566 versus cash generation of $214,241
in 2006. Total net working capital decreased from $1,201,720 on December 31,
2006 to $1,097,491 on December 31, 2007. Cash and cash equivalents increased
from $1,050,206 in 2006 to $1,077,772.


Full details of 2007 results including December 31, 2006 Financial Statements
and Management's Discussion & Analysis will be posted on sedar.com on April 2,
2008.


The company has licensed a new pharmaceutical product which will be launched in
quarter two, 2008.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024